Privia Health: The Compounder Quietly Admitted It Might Buy Back Its Own Stock

A raise-and-prune quarter came with a third-step escalation in capital-allocation language — and a cash-conversion haircut nobody asked about twice

PRVA · Earnings Call · 2026-11-05

The raise that came with a quiet haircut

Privia Health's Q3 was, on the surface, another installment in a very long, very boring compounding story. Implemented providers reached 5,893, up 12.2% year-over-year and 249 sequentially. Year-to-date practice collections grew 12% to $2.91 billion; adjusted EBITDA rose 21.9% to $114.7 million, or 28.8% of care margin. Guidance was lifted above the high end of the initial range for every key financial metric, and the company now expects 6,000 clinicians by year-end. “Given our strong year-to-date results, we are raising our 2026 outlook above the high end of our initial guidance for all key financial metrics.” — Parth Mehrotra, Chief Executive Officer · 2026-11-05 Then, in the Q&A, CFO David Mountcastle quietly trimmed the cash story: EBITDA-to-free-cash-flow conversion, previously guided at 70%–80%, is now 70%, and 70%–75% on a go-forward basis. “We are targeting right now 70%-75% as a full-time taxpayer.” — David Mountcastle, Chief Financial Officer · 2026-11-05 Management blamed the timing of MSSP settlements and the shift to full cash taxpayer status at a ~27% effective rate — a theme flagged back in August, when Parth Mehrotra waved off the CMS payment delay. “We're not that worried about it. They've been really good over the past many years.” — Parth Mehrotra, Chief Executive Officer · 2026-08-06 Fair enough. But note the sequencing: a business that has printed 112%, 121%, and 130% conversion in recent years is now guiding to 70%, with the top end of its own historical range removed. The free cash flow series is genuinely lumpy (≈ -$71M in 2026Q1, +$112M in 2025Q4), so this is a timing story, not a crack. Still, the language moved in one direction while the equity went the other.

The part nobody is paid to notice: revenue optics

Barclays' Andrew Mok asked the sharpest question on the call — why revenue beats keep outpacing care margin and EBITDA beats. The answer was accounting, not acceleration. “We acquired the Tax ID in Florida, so we own that medical group now” — Parth Mehrotra, Chief Executive Officer · 2026-11-05, Mehrotra said, meaning Privia Medical Group of Florida flipped from an administrative-services-only relationship into fully consolidated GAAP revenue. That explains the gap between total revenue of $633M, +21% year-over-year and the 12% practice-collections growth management keeps emphasizing. Investors modeling the top line off a consolidated-revenue slope should haircut it: the real economic engine is care margin, and that grew 16.3% at the 2026 midpoint.

Three acts, one direction: the buyback bar is being lowered

This is the actual news of the quarter, and it arrived in the last analyst question from Citizens' Constantine Davides. For four straight calls, Mehrotra's answer on returning capital was a polite no. In February: “we have the flexibility to return capital as a last resort if our stock price deviates meaningfully from what we think is intrinsic value.” — Parth Mehrotra, Chief Executive Officer · 2026-02-26 In May it escalated a notch: “our preference is to compound earnings and free cash flow and continue acquiring businesses with our balance sheet cash.” — Parth Mehrotra, Chief Executive Officer · 2026-05-08 On this call, the framing changed again.

Given where we sit today, and you talked about relative multiple on our own stock... the implied multiple now for our own stock is low teens. We still think the best accretive use is to acquire assets and compound the business, like we've done with a few deals. But I think we are at a point where, in the absence of M&A, I think the bar is lower for us to actually return capital.
Parth Mehrotra, Chief Executive Officer · 2026-11-05

He went further than he ever has, citing $500M+ of cash and $800M–$900M of total capacity including 2.5x leverage, and calling capital return "our responsibility" rather than an emergency valve. That is a company-unique pivot in tone, and it is corroborated by the balance sheet: effective net cash of $348M and rising, against a $3.06 billion market cap. The balance sheet strength that management has cited for a decade as an M&A war chest is now being reframed as an under-utilized asset.

Pruning the tree while buying the wreckage

The other fresh themes are structural. Privia is exiting its Surgery Partners partnership in Montana effective January 2027 — 69 providers, ~$23M of annual practice collections, immaterial to EBITDA — and Mehrotra's framing was notably unsentimental: “the bar for us to dilute ownership in any particular market is just very, very high.” — Parth Mehrotra, Chief Executive Officer · 2026-11-05 Meanwhile it is buying: American Choice Healthcare, the MSSP ACO carved out of Cano Health's Chapter 11, for ~$36M cash and 36,000 attributed lives across ten existing and three new states. “This was an example of the asset being available at very attractive multiples, well below where we trade.” — Parth Mehrotra, Chief Executive Officer · 2026-11-05 The keyword set captures it precisely: attractive multiples is new to the Privia lexicon, joining a reworked new capabilities pillar that explicitly name-checks ASC assets and ancillary services. That lands on live market ground: site of care and Ambulatory Surgery Center both appear among the global 90-day advancers, with ten positive tickers behind site-of-care. Privia has been arguing for several quarters that volumes will migrate out of the hospital; the tape is now agreeing with it. The cost trend question from BTIG — elevated but stable, with ambulatory good utilization versus inpatient noise — is the same debate Medical cost trend is having across the entire global healthcare-services cohort.

What the tape already says

Privia trades at 1.4x price-to-revenue, down 73% from its 2021 peak, and 96x price-to-net-income. The stock is -51.4% from its June 2021 high of $49.25 and -10.9% over the last 90 days, though it bounced 21% in the final five weeks into the print. Mehrotra's "low teens" pro-forma multiple claim only works if you strip out cash the market is not paying for. That is precisely why the buyback language matters more than the guidance raise. One thing to watch: receivables at 90.8% of revenue, up from 46% in 2020. Privia's cash conversion magic has long rested on a negative float — collect fast, disburse to providers later. That edge is being consumed. If it keeps eroding, 70%–75% conversion becomes the ceiling rather than the floor, and the buyback math gets tighter than the rhetoric.